17 Nov 08 Case Of Patient "Cured" Of HIV Baffles Doctors
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been “cured” by a bone marrow transplant given to treat his acute myeloid leukemia.
(more…)
Tags: Acute Myeloid Leukemia, American Patient, Baffles, Bone Marrow, Doctors, Hiv, Hiv Infection, Leukemia, Living In Berlin
12 Oct 08 Cyclacel Announces Completion Of Enrollment In Phase 2 Trial Of Sapacitabine In Elderly AML
lCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company’s oral nucleoside analogue, in elderly patients with acute myeloid leukemia (AML). Interim results from this trial are expected to be available by the end of 2008 and final results during the second half of 2009.
(more…)
Tags: Acute Leukemia, Acute Myeloid Leukemia, Clinical Trial, Cycc, Elderly Patients, Interim Results, Leukemia, Leukemia Aml, Nasdaq, Nucleoside Analogue, Oral, Pharmaceuticals Inc, Phase 2, Protocol, Second Half
12 Oct 08 Cyclacel Announces Completion Of Enrollment In Phase 2 Trial Of Sapacitabine In Elderly AML
lCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company’s oral nucleoside analogue, in elderly patients with acute myeloid leukemia (AML). Interim results from this trial are expected to be available by the end of 2008 and final results during the second half of 2009.
(more…)
Tags: Acute Leukemia, Acute Myeloid Leukemia, Clinical Trial, Cycc, Elderly Patients, Interim Results, Leukemia, Leukemia Aml, Nasdaq, Nucleoside Analogue, Oral, Pharmaceuticals Inc, Phase 2, Protocol, Second Half
15 Sep 08 Cyclacel Expands Phase 2 Sapacitabine Trial In Elderly AML To Include Patients With MDS
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for myelodysplastic syndromes (MDS). The MDS study is designed as a protocol amendment expanding the ongoing Phase 2 trial of sapacitabine in elderly patients with acute myeloid leukemia (AML) to include a cohort of patients with MDS.
(more…)
Tags: Acute Leukemia, Acute Myeloid Leukemia, Aml, Cohort, Cycc, Cyclacel Pharmaceuticals, Elderly Patients, Leukemia, Myelodysplastic Syndromes, Nasdaq, Pharmaceuticals Inc, Protocol Amendment
